Stefan de Vogel, James Van Schyndle, David Nimke, Mohamed A. Khalil, Ahsan M. Arozullah, N. Robinson,
Gastric cancer is the fifth most common cancer worldwide, representing ∼6% of new cancer cases. Zolbetuximab, an IgG1 monoclonal antibody, is being evaluated with chemotherapy for the treatment of advanced gastric or gastroesophageal junction (G/GEJ) cancer. Nausea and vomiting are commonly reported in these populations, and many of the patients underwent gastrectomy as prior treatment. The study aim was to assess the association between history of gastrectomy (total vs partial vs none) and risk of ...
Tópico(s): Helicobacter pylori-related gastroenterology studies
2021 - Elsevier BV | Annals of Oncology